title: A trial of the calcium antagonist felodipine in hypertensive type 2 diabetic patients.
abstract: Although calcium antagonists may impair insulin release in vitro, clinical studies have produced conflicting results. Felodipine is a highly selective dihydropyridine calcium antagonist effective in the treatment of hypertension. The efficacy of felodipine was assessed in a double-blind randomized placebo cross-over study of 21 Type 2 diabetic patients with primary hypertension, 13 men and 8 women, with an age of 61 (range 46-73) years. Thirteen were controlled on oral hypoglycaemic therapy and 8 on diet alone. Mean (SD) blood pressure (mmHg) was 176(20)/102(8) after a 2-4 week placebo run-in period, 169(21)/101(8) during the subsequent placebo period compared with 151(15)/88(9) after 4 weeks felodipine therapy (p less than 0.001). Nineteen patients required 5 mg twice daily and 2 patients 10 mg twice daily to achieve a target diastolic pressure of 95 mmHg. Side-effects seen with felodipine included ankle oedema, facial flushing, headache, and dizziness. During oral glucose tolerance tests performed after the felodipine and placebo phases, mean (SD) fasting blood glucose was 9.5(3.1) and 9.0(3.0) mmol l-1, respectively (NS), and the 90 min (peak) blood glucose was 19.1(4.8) and 18.1(4.8) mmol l-1, respectively (NS). Glycosylated haemoglobin and fructosamine concentrations likewise showed no significant changes.
authors.affiliation: Department of Medicine, Edinburgh Royal Infirmary, UK.
authors.forename: S
authors.initials: S
authors.lastname: Capewell
authors.forename: A
authors.initials: A
authors.lastname: Collier
authors.forename: D
authors.initials: D
authors.lastname: Matthews
authors.forename: C
authors.initials: C
authors.lastname: Hajducka
authors.forename: R
authors.initials: R
authors.lastname: Collier
authors.forename: B F
authors.initials: BF
authors.lastname: Clarke
authors.forename: A L
authors.initials: AL
authors.lastname: Muir
mesh_terms: D001053:Apolipoproteins / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D004311:Double-Blind Method; D015736:Felodipine / Q000627:therapeutic use*; D005260:Female; D019270:Fructosamine; D006442:Glycated Hemoglobin / Q000032:analysis; D006339:Heart Rate / Q000187:drug effects; D006595:Hexosamines / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
chemical_list: D001053:Apolipoproteins; D001786:Blood Glucose; D003404:Creatinine; D015736:Felodipine; D019270:Fructosamine; D006442:Glycated Hemoglobin; D006595:Hexosamines; D008055:Lipids